University of California, Davis
Davis, California, 95616, United States
NCT Number: NCT03476447
The REMEDI Study is a single-center, prospective, double-blind, randomized, placebo-controlled trial of multiple doses of B. infantis EVC001 supplementation in healthy term breastfed infants.
Looking for future studies?
Notify Me2 month–4 month
All sexes
Interventional
Not applicable
Davis, California, 95616, United States
Mother-infant dyads will be enrolled when the infant is 2-4 months of age. A 1-week lead-in period will be utilized to collect baseline microbiome samples and for the completion of daily and weekly feeding and health logs. Subjects that meet eligibility criteria on Day 7 will be randomized into 1 of 4 treatment arms. Supplementation will begin on Day 8 and will continue for a total of 28 consecutive days. Subjects will be followed for an additional 4 weeks after the cessation of the supplement. The total duration of the study will be approximately 9 weeks. Infant stool and urine samples, as well as maternal breast milk samples, will be collected on multiple occasions during the study. Mothers will be asked to complete questionnaires and health logs during the course of the study as well.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A once-daily oral feeding of B. infantis EVC001 will be mixed with breast milk and provided to infants for 28 consecutive days.
A once-daily oral feeding of a lactose placebo will be mixed with breast milk and provided to infants for 28 consecutive days.
Time frame: 28 days
The difference in levels of infant fecal B. infantis (as measured by B. infantis qPCR) between B. infantis EVC001 supplementation and placebo supplementation on Day 28.
Time frame: 28 days
The differences between B. infantis EVC001 doses on levels of infant fecal B. infantis (as measured by B. infantis qPCR) on Day 28.
Evolve BioSystems, Inc.
Industry
Rescuing the Microbiome Effectively With Different Doses of B. Infantis in Infants (The REMEDI Study)
Acronym: REMEDI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05793112
Food Protein Induced Allergic Proctocolitis, Gut Microbiome
Newton, Massachusetts, United States
View Trial DetailsNCT06883994
Fermented Vegetable Acceptability, Fermented Vegetable Intake
Davis, California, United States
View Trial DetailsNCT06911957
Affect (Mental Function), Anxiety Disorders
Reading, Berkshire, United Kingdom
View Trial DetailsNCT06900439
Glucose Control, Gut Microbiome
London, United Kingdom
View Trial Details